➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Johnson and Johnson
Boehringer Ingelheim
Baxter
Medtronic

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Litigation Details for GRUNENTHAL GMBH v. ACTAVIS ELIZABETH LLC (D.N.J. 2013)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in GRUNENTHAL GMBH v. ACTAVIS ELIZABETH LLC
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for GRUNENTHAL GMBH v. ACTAVIS ELIZABETH LLC (D.N.J. 2013)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 151 supplemental invalidity contentions regarding U.S. Patent No. RE39,593. Signed by Magistrate Judge Mark Falk on …2013 11 April 2017 2:13-cv-04507 830 Patent None District Court, D. New Jersey External link to document
0000-00-00 158 Proposed Claim Constructions For U.S. Patent Nos. RE39,593, 7,994,364 and 8,309,060 (Attachments: # 1 Declaration…2013 11 April 2017 2:13-cv-04507 830 Patent None District Court, D. New Jersey External link to document
2015-11-02 281 for Summary Judgment of Invalidity of U.S. Patent No. 8,309,060. (Attachments: # 1 Exhibit A, # 2 Exhibit… 25 July 2013 2:13-cv-04507 830 Patent None District Court, D. New Jersey External link to document
2016-01-18 309 written description of U.S. Pat. No. RE39,593 (the “’593 patent”) is contextualized by his understanding… that a patent lawyer and professor could not testify regarding what a “responsible patent examiner”…759 F.2d 10, 13 (Fed. Cir. 1985) (holding that a patent attorney could not testify on the appropriate… at *2 (D.N.J. Oct. 26, 2006) (holding that a patent attorney could not testify as an expert about the…LEXIS 21514 (D.N.J. July 27, 1996) (holding that “patent law experts” who were attorneys could not testify External link to document
0000-00-00 332 asserted patents are U.S. Reissue Patent 39,593 (the “RE593 Patent”), U.S. Patent 7,994,364 (the “364…364 Patent”), United States Patent 8,536,130 (the “130 Patent”), and United States Patent 8,309,060 … of four patent claim terms—three terms in the RE593 patent and one term in the ‘364 patent. Both the…Waxman Act. Plaintiffs in this patent infringement litigation assert four patents in six consolidated Subsequent…the RE593 patent and the ‘364 patent are being asserted against all defendants. The four claim External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.